NEWS
The T50 test measures calcification propensity in blood. It was developed for patients with chronic renal insufficiency (CNI). Researchers at the Univ...
Read More...
Calciscon AG announced today the closing for its Series A financing, led by Yellowstone Holding, for CHF 2.5M. The proceeds of the financing enable t...
Read More...
The proceeds of its CHF 600k pre-series A financing enables the company to initiate initial sales of its flagship product the T50 Calcification Propen...
Read More...
Fresenius Medical Care presented its T50 study of 776 hemodialysis patients at the European Nephrology (ERA-EDTA) Congress. The study confirms T50 as...
Read More...
A research team from University Groningen (NL) led by Prof. H. van Goor and Prof. M. de Borst, identified T50 as a new cardiovascular risk factor in t...
Read More...
"The winner of this year's INNOVATION AWARD of RWTH Aachen University, Germany, was a research team led by Prof. Dr. Schomburg from the Institute of M...
Read More...
The Board of Directors has appointed Vincent Linder as Chief Executive Officer (CEO). Dr. Pasch, co-founder and past-CEO, maintains his leadership rol...
Read More...
© 2022 by CALCISCON | Privacy Policy